These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 1909637

  • 21. Etofibrate therapy and effect of added low-dose cholestyramine in patients with combined hyperlipidaemia.
    Krüger B.
    Int J Clin Pharmacol Res; 1994; 14(5-6):177-83. PubMed ID: 7672874
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses.
    Calabresi L, Donati D, Pazzucconi F, Sirtori CR, Franceschini G.
    Atherosclerosis; 2000 Feb; 148(2):387-96. PubMed ID: 10657575
    [Abstract] [Full Text] [Related]

  • 24. Acipimox in combination with low dose cholestyramine for the treatment of type II hyperlipidaemia.
    Series JJ, Gaw A, Kilday C, Bedford DK, Lorimer AR, Packard CJ, Shepherd J.
    Br J Clin Pharmacol; 1990 Jul; 30(1):49-54. PubMed ID: 2390432
    [Abstract] [Full Text] [Related]

  • 25. Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia.
    Illingworth DR, Bacon S.
    Circulation; 1989 Mar; 79(3):590-6. PubMed ID: 2645064
    [Abstract] [Full Text] [Related]

  • 26. Effect of ciprofibrate treatment on biliary lipids in patients with hyperlipoproteinaemia.
    Angelin B, Einarsson K, Leijd B.
    Eur J Clin Invest; 1984 Feb; 14(1):73-8. PubMed ID: 6421601
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC, Brown LE, Stone PH, Silverman DI, Gibson CM, Sacks FM.
    Ann Intern Med; 1996 Oct 01; 125(7):529-40. PubMed ID: 8815751
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.
    Kłosiewicz-Latoszek L, Szostak WB.
    Eur J Clin Pharmacol; 1991 Oct 01; 40(1):33-41. PubMed ID: 2060543
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Gemfibrozil--the effect of biliary cholesterol saturation of a new lipid-lowering agent and its comparison with clofibrate.
    Hall MJ, Nelson LM, Russell RI, Howard AN.
    Atherosclerosis; 1981 Jul 01; 39(4):511-6. PubMed ID: 6942844
    [Abstract] [Full Text] [Related]

  • 34. Gemfibrozil in familial and type V hyperlipidaemias. Report of 3 cases.
    Varthakavi P, Turakhia DP, Sharma S, Salgaonkar DS, Nihalani KD, Joshi VR.
    J Assoc Physicians India; 1990 Nov 01; 38(11):860-2. PubMed ID: 2079473
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients.
    Sprecher DL, Abrams J, Allen JW, Keane WF, Chrysant SG, Ginsberg H, Fischer JJ, Johnson BF, Theroux P, Jokubaitis L.
    Ann Intern Med; 1994 Apr 01; 120(7):537-43. PubMed ID: 8093139
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.